Responses
Clinical/translational cancer immunotherapy
Original research
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.